Modality
Degrader
MOA
STINGag
Target
TROP-2
Pathway
Sphingolipid
SCD
Development Pipeline
Preclinical
~Oct 2011
→ ~Jan 2013
Phase 1
~Apr 2013
→ ~Jul 2014
Phase 2
~Oct 2014
→ ~Jan 2016
Phase 3
~Apr 2016
→ ~Jul 2017
NDA/BLA
Oct 2017
→ Jun 2031
NDA/BLACurrent
NCT04476536
2,829 pts·SCD
2024-07→2026-03·Active
NCT08145811
2,639 pts·SCD
2017-10→2031-06·Not yet recruiting
5,468 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-202w agoPh3 Readout· SCD
2026-05-051mo awayPh1 Dose Esc· SCD
2031-06-285.2y awayPh3 Readout· SCD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-03-20 · 2w ago
SCD
Ph1 Dose Esc
2026-05-05 · 1mo away
SCD
Ph3 Readout
2031-06-28 · 5.2y away
SCD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04476536 | NDA/BLA | SCD | Active | 2829 | UPCR |
| NCT08145811 | NDA/BLA | SCD | Not yet recr... | 2639 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |